Rising USA trichomoniasis cases propel demand for rapid tests, addressing the need for swift diagnosis of Trichomonas vaginalis.
NEWARK, DELAWARE, UNITED STATES OF AMERICA, November 24, 2023 /EINPresswire.com/ — The latest research by Future Market Insights forecasts an impressive trajectory for the global trichomonas rapid tests market. Projections indicate a notable CAGR of 5.3% during the anticipated period. The market, valued at US$ 437.6 Million in 2023, is anticipated to soar to US$ 733.0 Million by 2033.
The trichomonas rapid tests market closed at US$ 417.3 Million in 2022, showcasing an initial surge. Remarkably, an expected Year-on-Year (Y-o-Y) growth of 4.9% is forecasted for 2023, indicating a continued upward trend in market expansion.
Request a Sample Copy of the Report:
The global prevalence of sexually transmitted diseases (STDs) and sexual polygamy have a substantial impact on the Trichomonas rapid test industry. Considering STDs, including trichomoniasis, are so common over the world, there is a growing demand for rapid and effective diagnostic techniques.
According to the article published by International Journal of Pregnancy & Child Birth on January 20 2023, a study conducted at General Hospital Dutsin-ma examined 181 high vaginal swab samples. Participants who had four or more sexual partners had the highest prevalence of trichomoniasis (60%), followed by those who had three partners (41%), two partners (31%), and one partner (27%).
Likewise, sexual polygamy, in which individuals have several sexual partners, adds to the transmission and spread of STDs. Because of the increased risk and awareness of STDs among sexually polygamous people, there is an increasing demand for Trichomonas rapid tests.
These tests enable fast identification, diagnosis, and treatment of trichomoniasis, hence reducing infection transmission in sexual polygamous populations and increasing market growth for rapid testing solutions.
Key Takeaways from Market Study:
By product, rapid test strip contributed around US$ 159.1 Million in 2022. These strips are widely used since they provide rapid outcomes, require minimal equipment, and work well in point-of-care situations, which propels the market growth.
By sample type, vaginal/urethra swab contributed around US$ 331.8 Million in 2022. Trichomonas vaginalis can be precisely identified thanks to its practicality, non-invasiveness, and efficacy in collecting samples from the major sites of infection.
Hospitals contributed around one-third market share globally in 2022, This can be ascribed to the fact that significant population around the globe suffers from diseases, which can be adequately identified in these setting with qualified assistance.
By region, North America held dominant share in world in 2022 contributing around US$ 157.9 Million. The U.S. leads in this region with high prevalence of trichomoniasis.
“The rising cases of STIs and increase in multiple sexual polygamies contribute to its higher demand and global expansion.” opines Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI) analyst.
The trichomonas rapid test market is highly competitive, with key players including Common Sense Ltd. and Nanjing Liming Bio-products Co., Ltd . These companies are constantly participating in conferences, award competition with their products and launching new products to gain a larger market share, with a focus on affordability, convenience, and effectiveness.
In August 2018, Exeltis USA Inc. and Common Sense Ltd. entered into a distribution agreement for the distribution VS-Sense test swab product.
In January 2018, Nanjing Liming Bio-products Co., Ltd. received accreditation as UNICEF’s supplier.
Key Companies Profiled:
Home Health (UK) Ltd,
Norgen Biotek Corp.
Jei Daniel Biotech Corp
nal von minden GmbH
Elevate Your Business Strategy! Purchase the Report for Market-Driven Insights:
Key Market Segments Covered in Trichomonas Rapid Tests Industry Research:
Cassette Rapid Test Kit
Rapid Test Strip
Rapid Test Swab
Molecule Based Rapid Test Device
By Sample Type:
By End User:
Middle East and Africa (MEA)
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
Explore FMI’s related ongoing Coverage on Healthcare Market Domain:
Portable Medical Devices Market Size: The global portable medical devices market is projected to expand at a CAGR of 10.7% during the forecast period. The market is estimated to generate market revenue of US$ 163.84 billion by 2033, increasing from US$ 59.28 billion in 2023.
Pain Management Devices Market Share: The global demand for pain management devices is expected to grow at a healthy CAGR of 9% between 2022 and 2032, totaling a valuation of over US$ 5.68 Billion by the end of 2032.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.